Rituximab use in adult primary glomerulopathy: where is the evidence?

Rituximab is a chimeric anti-CD20 antibody that results in depletion of B-cell lymphocytes. It is currently used in the treatment of a variety of autoimmune diseases, in addition to CD20-positive lymphomas. The use of rituximab in the treatment of the adult primary glomerular diseases has emerged re...

Descripción completa

Detalles Bibliográficos
Autores principales: Mallat, Samir G, Itani, Houssam S, Abou-Mrad, Rana M, Abou Arkoub, Rima, Tanios, Bassem Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010164/
https://www.ncbi.nlm.nih.gov/pubmed/27621641
http://dx.doi.org/10.2147/TCRM.S114316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010164/
https://www.ncbi.nlm.nih.gov/pubmed/27621641
http://dx.doi.org/10.2147/TCRM.S114316

Ejemplares similares